Page 39 - Compass Pathways News Today

Author Bio Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing. Follow @alexcarchidi Investing in a new and rapidly expanding industry is a great way to bolster your portfolio, and its also qu...

Watch These Companies as Progress Made to Unleash the Potential of Psychedelics for Mental Diseases Thanks to the COVID-19 pandemic, research shows that people are suffering more than ever from mental health conditions like depression, anxiety and PTSD, where conventional medicines provide little to no relief. For decades now, one of the most meaningful breakthroughs in mental health therapeutics hasn’t been a traditional drug; it was Johnson & Johnson’s (NYSE: JNJ) Spravato (esketamin...

INN takes a closer look at some of the biggest ongoing psychedelic research studies that could shape the future of the industry. The psychedelics investment proposition is an enticing one for investors, and the bedrock of the industry is the potential attached to clinical research on psychedelic substances. Thanks to the groundbreaking progress of studies and trials evaluating psychedelic treatments, the entire sector is gaining more attention as a new age of medicine becomes a very real possib...

Atai Life Sciences could soon become the second psychedelics company to list on a major U.S. exchange. The Berlin-based biotech firm filed Tuesday with the SEC to raise $100 million in an IPO using the ticker symbol "ATAI." The company handles a growing portfolio of about 12 companies, all focused on bringing novel mental health treatments through various technologies. In most cases, these include the use of psychedelic substances in mental health treatment. Atai also owns about a 25% stake i...

This Could Be One of the Best Ways to Treat Mental Health Issues for Millions Over the last 20 years, “The number of psychopharmacological drugs research programs in larger drug firms has shrunk by 70% in the past decade,” reported The Guardian. “In general the larger companies have walked away from psychiatry. There are a few companies who have maintained efforts in the area but 70% tells you it’s been a pretty remarkable departure. Many withdrew from neuroscience entirely.” ...

Psychedelics Could be Your Next Multi-Billion-Dollar Opportunity It may only be a matter of time before mind-altering drugs make their way into Big Pharma treatments for mental health issues, such as depression, anxiety, obsessive compulsive disorder, trauma, and addiction. If that happens, the industry could be worth well over $100 billion, as noted by analyst at Eight Capital, benefiting companies such as Silo Wellness (CSE:SINO), Compass Pathways Inc. (NASDAQ:CMPS), HAVN Life Scie...

The group also has connected patients to doctors and therapists who oversee their use of the drug. These trial cases come amid mounting interest from researchers and investors, as well as a public push to reconsider bans on psilocybin, LSD, DMT, mescaline and other mind-altering substances such as MDMA, commonly known as ecstasy. The US state of Oregon legalized psilocybin for therapeutic use last November. Psychedelics have been used by indigenous peoples for millennia, but Western researchers...

To manage her stress and fears, Andrea Bird, who has terminal cancer, uses psychedelics, which are seeing a sudden re-emergence in Canada as a possible treatment for mental health conditions such as anxiety and depression. The 60-year-old Canadian was diagnosed with breast cancer in 2012. Despite aggressive treatment, the disease returned five years later, spreading to her lungs, bones and brain. As she tries to cope with her incurable ailment, Bird uses psilocybin, the psychoactive substance of...

  (Marcus Loke/Unsplash) There is no doubt that the psychedelic space is gaining momentum, and for investors, it is a perfect time to get in before the industry takes off.  As groundbreaking research continues to back up claims of the effectiveness of psilocybin for mental health conditions, psychedelics are poised to become the next big thing in mental health—and are catching the eye of investors in Canada and around the world. If you are caught wondering which the b...

Share this article Share this article PALM BEACH, Fla., April 14, 2021 /PRNewswire/ -- The psychedelics industry may appear to have suddenly emerged as one of the hottest corners of the stock market, but researchers have been working for decades to show the efficacy of these treatments and regulators are just starting to appreciate the possibilities.  Investors could see strong growth in the industry as companies commercialize breakthrough therapeutics while patients could finally have access...